Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

747
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
747
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

8.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.2K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.1K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

115
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
115

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating machine learning and pathway modelling to explore factors associated with chronic post-surgical pain and quality of life: a secondary observational analysis of the ENIGMA-II trial.

BJA open·2026
Same author

Prognostic value of the Duke Activity Status Index for preoperative cardiac risk stratification: an international pooled cohort study.

EClinicalMedicine·2026
Same author

Perioperative intravenous fluid and chronic kidney disease: long-term follow-up of the Restrictive versus Liberal Fluid Therapy in Major Abdominal Surgery (RELIEF) randomised trial.

British journal of anaesthesia·2026
Same author

The effect of intraoperative dexamethasone on glycaemic responses in people with diabetes mellitus: a preplanned analysis of the Perioperative ADministration of Dexamethasone and Infection trial.

British journal of anaesthesia·2026
Same author

Platform trials in anaesthesia and perioperative medicine: a scoping review.

BJA open·2026
Same author

Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial.

The Lancet. Respiratory medicine·2026

Related Experiment Video

Updated: Jul 16, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.3K

Tranexamic acid for haemostasis and beyond: does dose matter?

Tammy Lam1, Robert L Medcalf1, Geoffrey C Cloud2

  • 1Australian Centre for Blood Diseases, Monash AMREP Building, Monash University, Level 1 Walkway, Via The Alfred Centre, 99 Commercial Rd, Melbourne, 3004, Australia.

Thrombosis Journal
|September 12, 2023
PubMed
Summary

Tranexamic acid (TXA) effectively reduces bleeding by inhibiting plasminogen. However, its role in non-fibrinolytic effects, such as reducing post-surgical infections, requires further investigation regarding optimal dosage.

Keywords:
AmyloidFibrinolysisImmunityPharmacologySurgeryThrombosisTranexamic acid

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

924
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K

Related Experiment Videos

Last Updated: Jul 16, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.3K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

924
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Tranexamic acid (TXA) is a lysine analogue antifibrinolytic agent used since the 1960s to minimize blood loss.
  • TXA functions by competing for lysine binding sites on plasminogen and tissue-type plasminogen activator, thus preventing fibrin clot degradation.
  • Plasminogen also binds to other proteins and cell receptors, mediating effects beyond fibrinolysis, including roles in immunity and inflammation.

Purpose of the Study:

  • To explore the non-hemostatic applications of tranexamic acid.
  • To investigate whether established dosages for antifibrinolytic effects are suitable for modulating non-canonical plasmin actions.

Main Methods:

  • Literature review on tranexamic acid's mechanism of action.
  • Analysis of studies reporting TXA's effects on post-surgical infection rates.
  • Comparison of dosages used for hemostatic versus non-hemostatic indications.

Main Results:

  • TXA significantly reduces post-surgical infection rates, independent of its antifibrinolytic activity.
  • Evidence suggests plasmin plays a role in immunity and inflammation through interactions unrelated to fibrinolysis.
  • Optimal TXA dosages for reducing bleeding may not be directly applicable to blocking non-canonical plasmin effects.

Conclusions:

  • Tranexamic acid possesses potent non-fibrinolytic properties with potential applications in managing inflammation and infection.
  • Further research is needed to determine optimal dosing strategies for TXA's non-hemostatic indications.
  • Understanding plasmin's diverse roles is crucial for expanding TXA's therapeutic utility beyond hemorrhage control.